Allarity Therapeutics' Stenoparib Granted FDA Fast Track for Advanced Ovarian Cancer
Allarity's stenoparib gets FDA Fast Track for advanced ovarian cancer, aiming to expedite development for this serious condition and unmet medical need. A Phase 2 trial is enrolling patients, building on encouraging prior data.